Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean 167973 60 0?
Displaying drugs 1101 - 1125 of 1430 in total
Experimental
Matched Iupac: … {2,7}.0^{10,15}.0^{12,17}]nonadeca-2(7),3,5-trien-15-ium ... 14R,15R,16S,17S,18R)-13-ethyl-14,18-dihydroxy-8-methyl-15-propyl-8,15-diazahexacyclo[14.2.1.0^{1,9}.0^ …
ORP-101 is under investigation in clinical trial NCT04129619 (A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)).
Investigational
Matched Iupac: … ^{2,8}.0^{1,6}.0^{6,14}.0^{7,12}]icosa-7(12),8,10-trien-16-yl]-3,3-dimethylbutan-2-ol ... {1,6}.0^{6,14}.0^{7,12}]icosa-7(12),8,10-trien-11-yl]oxy}ethoxy)-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1 ... cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1^{2,8}.0^ …
MRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. It is a live biotherapeutic derived from the microbiota of a healthy human infant.
Investigational
Cositecan is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.
Investigational
Matched Iupac: … {4,9}.0^{15,20}]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione ... (19S)-19-ethyl-19-hydroxy-10-[2-(trimethylsilyl)ethyl]-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^ …
Investigational
Matched Iupac: … (19S)-19-ethyl-19-hydroxy-8-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa …
Experimental
Matched Iupac: … 4,8}.0^{13,18}]icos-17-en-16-one ... (1R,2S,4R,6R,8S,9S,12S,13R)-8-acetyl-6,9,13-trimethyl-6-phenyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{ …
Vidutolimod is a Toll-like receptor 9 (TLR9) agonist. It is an investigational cancer vaccine.
Investigational
Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy).
Investigational
Matched Iupac: … (2R)-14-fluoro-2-methyl-6,9,10,19-tetraazapentacyclo[14.2.1.0^{2,6}.0^{8,18}.0^{12,17}]nonadeca-1(18) …
Cinpanemab is under investigation in clinical trial NCT03318523 (Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease).
Investigational
Benzoctamine is a drug with two main uses. It can be used as a sedative which does not depress the respiratory system, but rather stimulates it. It can also be used as an anxiolytic with the same efficacy as chlordiazepoxide for treating anxiety neurosis.
Experimental
Matched Iupac: … methyl({tetracyclo[6.6.2.0²,⁷.0⁹,¹⁴]hexadeca-2,4,6,9,11,13-hexaen-1-yl}methyl)amine …
Aptazapine (CGS-7525A) was a tetracyclic antidepressant developed in the 1980s. Aptazapine had noradrenergic and specific serotonergic activity. It antagonised α2 adrenergic receptors approximately 10 times more effectively than mianserin, antagonised 5-HT2 receptors, agonised H1 receptors, and did not affect reuptake of serotonin or norepinephrine. Although Aptazapine reached clinical trials, it...
Experimental
Matched Iupac: … 17-methyl-6,14,17-triazatetracyclo[12.4.0.0²,⁶.0⁸,¹³]octadeca-2,4,8(13),9,11-pentaene …
AG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University. The candidate is a plasmid DNA vaccine developed using an intradermal gene transfer method targeting the SARS-CoV-2 spike protein. The gene transfer method increases the efficiency of gene expression and antibody production capability, garnering a more efficient DNA...
Investigational
Sponsored by Anges, Inc. in Japan, the AG0302-COVID19 is a DNA-based vaccine that recently completed Phase I/II trials (NCT04527081)[A226813, L30548].
Investigational
Experimental
Matched Iupac: … {1,10}.0^{2,8}]heptadecane-9-carboxylic acid ... 1R,2R,5R,8R,9S,10R,11S,12S)-12-hydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.1^{5,8}.0^ …
Nalorphine is a mixed opioid agonist–antagonist. It acts at two opioid receptors—at the mu receptor it has antagonistic effects, and at the kappa receptors it exerts high-efficacy agonistic characteristics. It is used to reverse opioid overdose and (starting in the 1950s) in a challenge test to determine opioid dependence.
Experimental
Vet approved
Matched Iupac: … (1S,5R,13R,14S,17R)-4-(prop-2-en-1-yl)-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca …
Experimental
Matched Iupac: … {1,10}.0^{2,8}]heptadec-13-ene-9-carboxylic acid ... ,5S,8S,9S,10R,11R,12S)-5,12-dihydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.1^{5,8}.0^ …
Experimental
Matched Iupac: … 1-(2-{1-ferra-1,1'-spirobi[pentacyclo[2.2.0.0^{1,3}.0^{1,5}.0^{2,6}]hexane]-2-yl}ethyl)-2,5-dihydro-1H-pyrrole …
A noncompetitive antagonist at GABA-A receptors and thus a convulsant. Picrotoxin blocks the gamma-aminobutyric acid-activated chloride ionophore. Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates. [PubChem]
Experimental
Matched Iupac: … -trioxapentacyclo[6.4.1.1^{9,12}.0^{3,5}.0^{5,13}]tetradecane-6,11-dione ... 5S,8S,13R,14S)-1-hydroxy-14-(2-hydroxypropan-2-yl)-13-methyl-4,7,10-trioxapentacyclo[6.4.1.1^{9,12}.0^ ... {3,5}.0^{5,13}]tetradecane-6,11-dione; (1R,5S,8S,13R,14R)-1-hydroxy-13-methyl-14-(prop-1-en-2-yl)-4,7,10 …
Experimental
Illicit
Matched Iupac: … .0^{7,18}]octadeca-7(18),8,10,15-tetraen-4-ium bromide ... (1S,5R,13R,14S,17R)-14-hydroxy-10-methoxy-4,4-dimethyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17} …
Experimental
Matched Iupac: … 4,9}.0^{15,20}]icosa-1(13),3(11),4(9),5,7,15(20),16,18-octaene-1,3-bis(ylium) ... 7,17-bis(diaminomethyl)-12-oxo-1lambda5,3lambda5,10,14-tetraaza-2-zincapentacyclo[11.7.0.0^{3,11}.0^{ …
Experimental
Illicit
Matched Iupac: … (1S,4S,5R,13R,14S,17R)-14-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0
Experimental
Matched Iupac: … {4,9}.0^{15,20}]henicosa-2(10),4,6,8-tetraene-19-carboxylate ... diethylamino)ethyl]-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyloxy)-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^ …
Experimental
Illicit
Matched Iupac: … (1S,5R,13R,14S,17S)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10 …
Illicit
Matched Iupac: … (1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6-oxa-5,7-diazapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18 …
Esmirtazapine, known by the standardized identifier SCH 900265, was under development by Organon to treat insomnia and vasomotor symptoms associated with menopause. Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology. This includes inverse agonist activity of H1 and 5-HT2 receptors and antagonism of α2-adrenergic receptors. Merck has...
Investigational
Matched Iupac: … (7S)-5-methyl-2,5,19-triazatetracyclo[13.4.0.0²,⁷.0⁸,¹³]nonadeca-1(15),8,10,12,16,18-hexaene …
Displaying drugs 1101 - 1125 of 1430 in total